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Abstract
Somatostatin (ST) inhibits gastrointestinal motility and exocrine and endo­
crine secretions. In animals, ST has been demonstated to decrease food intake. 
We investigated, in a randomized double-blind investigation in 10 healthy 
humans, the effects of an intravenous ST infusion compared to saline on sub­
jective hunger feelings. After 1 h, a low dose of fat was given intraduodenally 
to induce the release of endogenous upper-intestinal satiety factors. Ninety 
minutes later sandwiches were served and eaten until satiation. In the first 
hour, when no intraduodenal fat was given, there was a significant decrease in 
feelings of hunger with ST (p < 0.05). During the intraduodenal fat infusion 
this pattern reversed with a trend towards less satiety with ST. Food intake 
during intraduodenal fat infusion tended to be higher during ST (305 ±  42 g) 
than during saline (205 ± 36 g) although not significantly. In the 5 h after the 
experiment hunger feelings were significantly less after ST. In conclusion, we 
found evidence for a satiety effect of ST in humans which reversed towards 
less satiety when intraduodenal intralipid, which presumably produced endog­
enous satiety factors, was given. Postmeal satiety is higher after ST.
Introduction
Somatostatin is a cyclic tetradecapeptide with a distri­
bution throughout the nervous system, the gastrointesti­
nal tract, and other parts of the body [1]. Among its 
actions are the inhibition of the release of several gastroin­
testinal peptides including gastrin [2], secretin [3], vasoac­
tive intestinal polypeptide [4], cholecystokinin [5], and 
motilin [6], as well as insulin [7, 8] and glucagon [7], In 
addition, somatostatin has been demonstrated to affect 
end-organ responses to selected stimuli in several animal 
species. For example, direct inhibition of human parietal 
cell secretion of acid [9, 10], pancreatic acinar cell secre­
tion of enzymes [11], (3-cell secretion of insulin [7], and 
primate resting lower esophageal sphincter pressure [ 12] 
have been reported. Furthermore, it has been demon­
strated that exogenous ST inhibits motility functions in 
the human gastrointestinal tract [13]. In animals ST has 
been demonstrated to decrease food intake [14-16],
In the present study, we wanted to investigate the satie­
ty effects of ST in humans, basally, during low-dose intra­
duodenal intralipid infusion which may induce release of 
gastrointestinal hormones without disturbing gastrointes­
tinal motility, and postprandially.
Subjects and Methods
Ten healthy volunteers (5 M, 5 F, mean age 26) participated in 
this double-blind, randomized study. Informed consent was obtained 
from all subjects. The study was approved by the local ethics commit­
tee of the University of Leiden.
For every experiment each subject presented, after an overnight 
fast, at 8 a.m. at our research unit where a PVC Freka tube CH8 was 
introduced through one of the nostrils into the duodenum using a 
guide wire. After correct positioning as ascertained by fluoroscopy 
the guide wire was removed and the tube fixed to the nose. The fol­
lowing hour the volunteers accustomed to the intraduodenal tube 
and at 9 a.m. an intravenous catheter was placed into each forearm.
From one catheter blood was drawn from 9.15 a.m. (t(time) -  15 
min) at 15-min intervals until the end of the study at 1 p.m. for deter-
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mination of plasma CCK. The other catheter was used for infusion of 
saline or ST from 9.30 a.m. (t = 0 min) until 1 p.m. (t = 210 min).
At 9.30 a.m. (t = 0 min), the intravenous infusion of saline or 
somatostatin [14] (UCB, Brussels, Belgium, 125 (ig/h after a loading 
dose of 125 |xg) was started. This dose was given because we and oth­
ers previously found that higher doses increased abdominal discom­
fort and nausea [13]. At t = 60 min the intraduodenal infusion of 
intralipid 20% (KabiVitrum®) 30 ml/h was started. From t = 60 min 
until the end of the infusion at t = 210 min 15 g intralipid was infused 
into the duodenum.
At noon (t = 150 min) identical sandwiches with 10 g margarine 
and 15 g cheese (3.33 kcal/g) were served and the volunteers were 
invited to eat until they were fully satiated. The amount eaten was 
carefully determined as was the duration of the meal. They were 
allowed to drink mineral water (without carbon dioxide) as wanted.
Basally and every 15 min hunger feelings, fullness feelings, pro­
spective feeding intentions and wish to eat were scored as hunger 
parameters on 100-mm visual analogue scales as described by Blun­
dell and Burley [17] and Silverstone [18].
The subjects were also asked to fill in these hunger scores at home 
after the experiment at 2 ,3 ,4 ,5  and 6 p.m. to assess satiety.
As described by Hill [19] and modified to Dutch feeding customs, 
every 30 min from t = 0 min to t = 210 min, a list and photograph of 6 
protein-rich, 6 fat-rich, 6 carbohydrate-rich items (the amount of 
each item on the photograph containing 200 kcal) and 6 low-energy 
items were presented. From each of these 24 items the subjects were 
asked if they wanted to eat the amount shown, double the amount, 
half the amount or nothing independent of the other items. At each 
time interval the total amount of caloric items was calculated (half 
the amount = % caloric item, double the amount is 2 caloric items). 
Also, the amount of protein, fat and carbohydrate items that the sub­
jects wanted to eat was calculated independently. Plasma CCK was 
determined in one run using a sensitive and specific radioimmunoas­
say as has previously been described. The intra-assay variation was 
between 4.6 and 11.5% [20].
Results are expressed as means ± SEM. Statistical analysis of 
hunger feelings was performed by calculating the integrated area 
under the curve followed by Wilcoxon’s test for paired results. These 
nonparametric tests were also used for the other comparisons.
Results
During the first 60 min, when no intraduodenal fat was 
given there was a significant decrease in hunger during ST 
infusion compared to saline (p < 0.05). The same trend 
was seen for the other hunger parameters (fig. 1, 2).
During the intraduodenal fat infusion this pattern 
reversed with a trend towards less satiety with ST 
(fig. 1,2). There were no significant differences for the 
protein, fatty or carbohydrate-rich items. Food intake 
during the intraduodenal fat infusion was higher during 
ST (305 ± 42 g) than during saline (205 ± 36 g) although
not significantly.
In the 5 h after the experiment, feelings for hunger, 
wish to eat and prospective feeding were significantly less
after ST (p < 0.05) (fig. 3).
Mean basal plasma CCK was comparable in the saline 
(2.6 ±0 .1  pM ) and ST experiment (2.9 ±  0.4 pM). In the 
first 60 min of the intravenous infusion ST induced a sig­
nificant decrease in plasma CCK to 1.9 ±  0.2 pM  (p <  
0.01). During the intraduodenal fat infusion plasma CCK 
did not change anymore (fig. 4). In the saline experiment 
there was a significant increase in plasma CCK during the 
intraduodenal fat infusion to 4.8 ± 0 .4  pM  at t = 150 min 
(p <  0.001).
During the experiments no adverse effects were re­
corded, but 3 of the 10 subjects reported nausea in the 
afternoon after ST infusion.
Discussion
This study indicates that ST may also induce satiety in 
humans. We hypothesize that the reversal towards less 
satiety with ST compared to saline after the intraduodenal 
intralipid infusion may be explained by inhibition of 
endogenous satiety factors by ST.
In the first hour, when no intraduodenal fat was given, 
there was a trend to more satiety with ST for all parame­
ters tested which reached significance for the hunger feel­
ings (p < 0.05). During the low-dose intraduodenal fat 
infusion, which presumably induced the release of endog­
enous satiety factors, this pattern reversed with a trend 
(most clearly in the last 15 min) towards less satiety dur­
ing ST and also food intake thereafter was nearly 50% 
higher during ST.
Cholecystokinin (CCK) may be an important endoge­
nous satiety factor. In many studies in animals and 
humans it has been demonstrated that CCK decreases 
food intake [21-25]. We have shown that ST prevents the 
release of CCK during low-dose intraduodenal intralipid 
infusion. ST also prevents the release of other hormones, 
some of which may have satiety effects [ 1 ]. We hypothe­
size that the inhibition of the release of endogenous satie­
ty factor during low-dose intraduodenal fat infusion is the 
mechanism whereby ST may decrease satiety and in­
crease food intake in that period.
In animals ST has been demonstrated to decrease food 
intake [14, 15]. We have now shown that ST may also 
have satiety effects in humans, because hunger feelings 
were significantly less with ST in the first hour of our 
experiments and in the hours after the experiment. The 
mechanism whereby ST induces satiety may involve 
effects on gastrointestinal motility, gastrointestinal hor­
mones or a direct effect of ST as a neurotransmitter or a 
satiety agent. It is also possible that ST acts by direct stim-
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Fig. 1. Hunger, wish to eat, fullness and prospective feeding intentions during saline (dots point) or somatostatin 
(asterisk) (ST) infusion (a loading dose of 125 |xg followed by 125 ng/h). Differences form basal are plotted. From t = 
60 till t = 150 an intraduodenal infusion of 6 g intralipid 20%/h was given. Feelings of hunger were significantly less 
during the first 60 min of ST infusion (p<0.05).
Items
Fig. 2. Food selection. Wish to eat caloric 
items during saline (dots point) or somatos­
tatin (asterisk) infusion (a loading dose of 
125 jig followed by 125 M-S^ h). Differences 
from basal are plotted. From t = 60 till t = 
150 an intraduodenal infusion of 6 g intrali­
pid 20%/h was given.
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Fig. 3. Hunger, wish to eat, fullness and prospective feeding intentions in the hours after the saline (dots point) or 
somatostatin (asterisk) (ST) infusion (a loading dose of 125 (.ig followed by 125 |ig/h). Differences from basal are 
plotted. Hunger, wish to eat and prospective feeding intentions were significantly less after ST (p <  0.05).
Fig. 4. Plasma cholecystokinin levels 
during saline (dots point) or somatostatin 
(asterisk) infusion (a loading dose of 125 jig 
followed by 125 jig/h).
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ulatiun of digestive sensorv endinas or indirectly bv inter- time in man [ 13]. This disturbed motility may contribute
ference with release or action of mediators of satiety, to  the satiety o r even nausea-inducing effects of ST.
Also the interference with absorption of the meal mayInteractions between ST and the svstem on
the one hand and with CCK on the other may also be contribute to the satiety effects of ST after the meal [13,28,
involved [2b], Activation of the somatostatin receptor is 29] and the higher food intake may also have contributed to
linked with various guanine nucleotide binding proteins the prolonged satiety. In rats there is evidence that ST
with different physiological actions [26]. STs universal reduced feeding by a vagally mediated mechanism and that
inhibitory effect is believed to be due to intracellular this decrease in food intake is not due to illness or malaise
*
dephosphorylation of cellular proteins by phosphatases [14-16]. This is rather similar to the satiety effects of CCK
[26]. The final step in somatostatin action appears to be which are also mediated through the vagus nerve [ 15].
its ability to inhibit gene expression [26] In conclusion, we found evidence for a satiety effect of
It has been demonstrated that the long-acting somato- ST which reversed towards less satiety when a low7 dose of
statin analogue sandostatin (SMS) induces a threefold intraduodenal fat, which presumably induced endoge-
prolongation of mouth to cecum transit time [27,28] and nous satiety factors, was given. Postmeal satiety is higher
also ST dose-dependently prolonged intestinal transit after ST.
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